Skip Navigation

This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (15)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Anelli, A.
Right arrow Articles by Soares, F.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Anelli, A.
Right arrow Articles by Soares, F.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Annals of Oncology 14:428-432, 2003
© 2003 European Society for Medical Oncology

Original Paper

Correlation of p53 status with outcome of neoadjuvant chemotherapy using paclitaxel and doxorubicin in stage IIIB breast cancer

A. Anelli1,+, R. R. Brentani2, A. P. Gadelha1, A. Amorim de Albuquerque1 and F. Soares1

1 Department of Medical Oncology, Hospital do Câncer de São Paulo, São Paulo; 2 Ludwig Institute for Cancer Research, São Paulo, Brazil

Received 21 May 2002; revised 24 September; accepted 22 October 2002

Background:

The role of p53 in modulating apoptosis has suggested that it may affect efficacy of anticancer agents. We prospectively evaluated p53 alterations in 73 patients with locally advanced breast cancer (IIIB) submitted to neoadjuvant chemotherapy.

Patients and methods:

Patients received three cycles of paclitaxel (175 mg/m2) and doxorubicin (60 mg/m2) every 21 days. Tumor sections were analyzed before treatment for altered patterns of p53 expression using immunohistochemistry and DNA sequencing.

Results:

An overall response rate of 83.5% was obtained, including 15.1% complete pathological responses. The regimen was well tolerated with 17.7% grade 2/3 nausea and 12.8% grade 3/4 leukopenia. There was a statistically significant correlation between response and expression of p53. Of the 25 patients who obtained a complete clinical response, two were classified as positive (P = 0.004, {chi}-square). Of 11 patients who obtained a complete pathological remission, one was positive (P = 0.099, {chi}-square).

Discussion

The combination is highly effective in locally advanced breast cancer. A negative expression of p53 indicates a higher chance of responding to this regimen. The p53 status may be used as a biological marker to identify those patients who would benefit from more aggressive treatments.

Key words: breast cancer, doxorubicin, locally advanced, p53, paclitaxel


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Anticancer ResHome page
S.-I. YAMASHITA, M. CHUJO, T. MOROGA, K. ANAMI, K. TOKUISHI, M. MIYAWAKI, Y. KAWANO, S. TAKENO, S. YAMAMOTO, and K. KAWAHARA
DYRK2 Expression May be a Predictive Marker for Chemotherapy in Non-small Cell Lung Cancer
Anticancer Res, July 1, 2009; 29(7): 2753 - 2757.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
S. J. Kim, Y. Miyoshi, T. Taguchi, Y. Tamaki, H. Nakamura, J. Yodoi, K. Kato, and S. Noguchi
High Thioredoxin Expression Is Associated with Resistance to Docetaxel in Primary Breast Cancer
Clin. Cancer Res., December 1, 2005; 11(23): 8425 - 8430.
[Abstract] [Full Text] [PDF]

Home page
 Endocr Relat CancerHome page
P J Barrett-Lee
Growth factor signalling in clinical breast cancer and its impact on response to conventional therapies: a review of chemotherapy
Endocr. Relat. Cancer, July 1, 2005; 12(Supplement_1): S125 - S133.
[Abstract] [Full Text] [PDF]

Home page
 The OncologistHome page
S. H. Giordano
Update on Locally Advanced Breast Cancer
Oncologist, December 1, 2003; 8(6): 521 - 530.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
A. Bottini, L. Dogliotti, A. Bersiga, M. P. Brizzi, and A. Berruti
p53 expression and disease outcome of breast cancer patients undergoing primary chemotherapy with anthracycline-containing regimens
Ann. Onc., July 1, 2003; 14(7): 1156 - 1156.
[Full Text] [PDF]


Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.